(Q40205104)

18 September 2017

title

The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells (English)

1 reference

18 September 2017

1 reference

6

1 reference

18 September 2017

B ten Cate

1

1 reference

18 September 2017

D F Samplonius

2

1 reference

18 September 2017

T Bijma

3

1 reference

18 September 2017

L F M H de Leij

4

1 reference

18 September 2017

W Helfrich

5

1 reference

18 September 2017

publication date

23 November 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

21

1 reference

18 September 2017

issue

2

1 reference

18 September 2017

page(s)

248-252

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404477

18 September 2017

exact match

0 references

cites work

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Mechanisms of action of valproate: a commentatory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Establishment and characterization of a human histiocytic lymphoma cell line (U-937)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

7 January 2021

Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

7 January 2021

Antitumor activity of sodium valproate in cultures of human neuroblastoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

7 January 2021

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404477

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404477

1 reference

Dimensions Publication ID

18 September 2017

1017160481

0 references

1 reference